ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Kane Biotech Inc

Kane Biotech Inc (KNE)

0.13
0.00
( 0.00% )
Updated: 10:28:52

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
0.13
Bid
0.135
Ask
0.145
Volume
100
0.00 Day's Range 0.00
0.05 52 Week Range 0.19
Market Cap
Previous Close
0.13
Open
-
Last Trade
100
@
0.13
Last Trade Time
10:17:36
Financial Volume
-
VWAP
-
Average Volume (3m)
140,889
Shares Outstanding
131,844,000
Dividend Yield
-
PE Ratio
-3.25
Earnings Per Share (EPS)
-0.04
Revenue
2.82M
Net Profit
-5.27M

About Kane Biotech Inc

Sector
Coml Physical, Biologcl Resh
Industry
Coml Physical, Biologcl Resh
Headquarters
Winnipeg, Manitoba, Can
Founded
-
Kane Biotech Inc is listed in the Coml Physical, Biologcl Resh sector of the TSX Venture Exchange with ticker KNE. The last closing price for Kane Biotech was $0.13. Over the last year, Kane Biotech shares have traded in a share price range of $ 0.05 to $ 0.19.

Kane Biotech currently has 131,844,000 shares outstanding. The market capitalization of Kane Biotech is $17.14 million. Kane Biotech has a price to earnings ratio (PE ratio) of -3.25.

KNE Latest News

Kane Biotech Announces Exercise of Warrants

WINNIPEG, Manitoba, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces the exercise of an aggregate of 5 million warrants at an...

Kane Biotech Announces Second Quarter 2024 Financial Results

WINNIPEG, Manitoba, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announces its second quarter 2024 financial...

Kane Biotech Announces new DispersinB® Publication in Pathogens and Conference Presentations

WINNIPEG, Manitoba, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces the publication of a new review article on DispersinB® in...

Kane Biotech Announces Distribution Agreement with Qatar Datamation Systems for revyve™ Antimicrobial Wound Gel

WINNIPEG, Manitoba, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has signed a three year distribution...

Kane Biotech to Release Second Quarter 2024 Financial Results on August 29, 2024 – Conference Call to Follow

WINNIPEG, Manitoba, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”) will announce its second quarter 2024 financial results after market close on...

Kane Biotech Announces Distribution Agreement with Razan Medical Trading for revyve™ Antimicrobial Wound Gel

WINNIPEG, Manitoba, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has signed a three year distribution...

Kane Biotech Receives Funding Support to Expand the revyve™ Antimicrobial Wound Gel Family

WINNIPEG, Manitoba, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that it is receiving advisory services and...

Kane Biotech Receives FDA Approval to Increase Dosage Allowance of its revyve™ Antimicrobial Wound Gel

WINNIPEG, Manitoba, July 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that the US Food and Drug Administration...

Kane Biotech Receives ISO 13485:2016 MDSAP Quality Certification

WINNIPEG, Manitoba, July 17, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has received ISO 13485:2016 Medical Device Single...

Kane Biotech Announces Issuance of Restricted Share Units

WINNIPEG, Manitoba, July 15, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), today announces that it has issued 4,213,133 restricted share...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.02-13.33333333330.150.160.121037450.14401908CS
4-0.015-10.34482758620.1450.170.12928880.15072133CS
120.03300.10.170.091408890.13819005CS
260.0562.50.080.170.05985260.12278187CS
52-0.045-25.71428571430.1750.190.05686030.11777924CS
156-0.01-7.142857142860.140.260.05691700.13627135CS
2600000.145000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TBIXTrustbix Inc
$ 0.02
(300.00%)
6.04M
GTM.PG2M Cap Corp
$ 0.025
(150.00%)
38k
IBOUniversal Ibogaine Inc
$ 0.01
(100.00%)
48.31k
MTXMetalex Ventures Ltd
$ 0.015
(50.00%)
2.06k
SDRStroud Resources Ltd
$ 0.07
(40.00%)
44k
GDNP.HGood Natured Products Inc
$ 0.005
(-50.00%)
36.4k
DMDataMetrex AI Limited
$ 0.01
(-33.33%)
917k
CLMConsolidated Lithium Metals Inc
$ 0.01
(-33.33%)
500.2k
VISVisionstate Corp
$ 0.035
(-30.00%)
319.08k
ZBNIZeb Nickel Corp
$ 0.035
(-30.00%)
44.48k
TBIXTrustbix Inc
$ 0.02
(300.00%)
6.04M
CTMCanterra Minerals Corp
$ 0.04
(-11.11%)
3.78M
JHCJinhua Capital Corporation
$ 0.01
(0.00%)
3.66M
GRSLGR Silver Mining Ltd
$ 0.16
(0.00%)
1.89M
ABIAbcourt Mines Inc
$ 0.045
(12.50%)
1.11M

KNE Discussion

View Posts
teq0904 teq0904 9 months ago
They have been making about 2,500 samples per month in their lab for distribution to doctors for more than a month. By the time the contract plant starts up at the end of March there will be over 10k samples out so lots of doctors will be familiar with the product. You can bet they went to the burn centers and other of their top identified markets first.
👍️0
teq0904 teq0904 11 months ago
Latest video on kne
https://www.facebook.com/KaneBiotechInc/videos/292568703569665
👍️0
teq0904 teq0904 1 year ago
cc on Tuesday
👍️0
teq0904 teq0904 1 year ago
Doesn't matter what you think the dog market is, because it will be sold. Strategic review nr.
👍️0
teq0904 teq0904 1 year ago
First closing of the financing is probably next week. Officers and directors are in on it.
👍️0
teq0904 teq0904 1 year ago
On the previous cc, Edwards said it is possible that the FDA will approve the manufacturing plant in time for the sales to start in Q4.
👍️0
teq0904 teq0904 1 year ago
The next quarterly cc will be late in August.
👍️0
teq0904 teq0904 1 year ago
The next step is for the outsourced manufacturing of coactiv+ to be completed. It may already be done, but it was supposed to take 3 months after receiving FDA approval.
👍️0
teq0904 teq0904 1 year ago
They have FDA approval for coactiv+.
👍️0
J_Dean J_Dean 3 years ago
This is the year. Let’s go! :)
👍️0
Golden Cross Golden Cross 5 years ago
Kane Biotech Announces Third Quarter 2019
Financial Results

https://backend.otcmarkets.com/otcapi/company/dns/news/document/40388/content
👍️0
Golden Cross Golden Cross 5 years ago
KNBIF Website:

https://www.kanebiotech.com/
👍️0
Golden Cross Golden Cross 5 years ago
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (56 patents and patents pending, trade secrets and trademarks) and products developed by the Company’s own biofilm research expertise and acquired from leading research institutions. StrixNBTM, DispersinB®, Aledex®, bluestemTM, AloSeraTM, coactiv+TM and Kane® are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE".
👍️0
Golden Cross Golden Cross 5 years ago
Monster # of filings today $KNBIF

https://www.otcmarkets.com/stock/KNBIF/disclosure
👍️0
sfld sfld 5 years ago
This might pump this week. Mentioned in a National Inflation Association newsletter today. GLTA
👍️0
pegcitygreen pegcitygreen 5 years ago
I live in Winnipeg and have personally worked with this company. Great people, great products, but the company itself always seems to struggle. Kane products are for wealthy/well off people who love their pets and more than likely do not have any kids. A very, very niche market. Their tradeshows booth is quite impressive...but that doesn't mean impressive sales.
👍️0
teq0904 teq0904 6 years ago
CEO got 2M shares in the market now.
👍️0
teq0904 teq0904 6 years ago
Jan 30 cc and presentation shows the potential markets. Just sign into it and you end up with the archive. https://edge.media-server.com/m6/p/rzpqebyy
👍️0
Macaveli Macaveli 6 years ago
Decent news released today. Plus insiders are buying. This is a hidden gem.
👍️0
teq0904 teq0904 6 years ago
Sales are slow for this startup, however the products are superb so I imagine it will be a good company in the long run. I used the oral rinse and shampoo for my dog. I don't know if the rinse is the reason, but the vet told me this month that her teeth are in excellent shape for her age.
She also had a bad itch last winter and scratched day and night. It didn't stop with the use of a vet's prescription shampoo, so I tried the Kane product with excellent results. As soon as I put it on her she stops scratching for about 1 day, so I just apply it once daily wherever I see her scratching.

I know a guy who had terrible psoriasis itching on the scalp all day and night long but it all stopped when he used the human shampoo.
👍️0

Your Recent History

Delayed Upgrade Clock